Amgen Q2 Sales Rise, But Growth Depends On Repatha And Beyond
This article was originally published in The Pink Sheet Daily
Executive Summary
Execs faced questions about commercial preparations and potential label for Amgen’s PCSK9 inhibitor, we well as speculation about what the appointment of former Schering CEO Fred Hassan to the board means for Amgen’s M&A strategy.